SENORES

Senores Pharmaceuticals Share Price

 

 

Invest in Senores Pharmaceuticals with 3.04X leverage

Invest with MTF

Performance

  • Low
  • ₹758
  • High
  • ₹813
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹877
  • Open Price₹790
  • Previous Close₹790
  • Volume246,226
  • 50 DMA₹798.45
  • 100 DMA₹761.09
  • 200 DMA₹687.98

Investment Returns

  • Over 1 Month -0.09%
  • Over 3 Month + 12.74%
  • Over 6 Month + 29.09%
  • Over 1 Year + 53.4%

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 42.6
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 3,712
  • P/B Ratio
  • 4.6
  • Average True Range
  • 31.99
  • EPS
  • 18.92
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.82
  • RSI
  • 48.1
  • MFI
  • 47.1

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹805.95
+ 15.9 (2.01%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹815.07
  • 50 Day
  • ₹798.45
  • 100 Day
  • ₹761.09
  • 200 Day
  • ₹687.98

Resistance and Support

792.13 Pivot Speed
  • R3 881.77
  • R2 847.28
  • R1 826.62
  • S1 771.47
  • S2 736.98
  • S3 716.32

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Senores Pharmaceuticals develops and manufactures niche, complex, and specialty pharmaceutical products adhering to international quality standards. With a global focus, the company is committed to innovation, affordable healthcare, and meeting the evolving demands of the healthcare industry.

Senores Pharmaceuticals Ltd has an operating revenue of Rs. 516.98 Cr. on a trailing 12-month basis. An annual revenue growth of 92% is outstanding, Pre-tax margin of 18% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 18% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart and is trading around -5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 94 which is a GREAT score indicating consistency in earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 99 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-20 Quarterly Results & Others To consider other business matters.
2026-01-07 Others Inter alia, 1. To consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group.
2025-11-06 Quarterly Results
2025-07-23 Quarterly Results & Others To consider other business matters.
2025-05-15 Audited Results

Senores Pharmaceuticals F&O

Senores Pharmaceuticals Shareholding Pattern

45.8%
4.88%
2.66%
3.35%
0.01%
31.95%
11.35%

About Senores Pharmaceuticals

  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • Managing Director
  • Mr. Swapnil Jatinbhai Shah
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹805 As on 20 January, 2026 | 07:45

The Market Cap of Senores Pharmaceuticals is ₹3711.7 Cr As on 20 January, 2026 | 07:45

The P/E ratio of Senores Pharmaceuticals is 42.6 As on 20 January, 2026 | 07:45

The PB ratio of Senores Pharmaceuticals is 4.6 As on 20 January, 2026 | 07:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23